Ipamorelin vs GHRP-2: What the Research Compares

Ipamorelin and GHRP-2 are both synthetic peptides in the growth hormone secretagogue class. They appear together in analytical chemistry, metabolism and anti-doping literature far more often than in clinical trials, and readers comparing them are usually trying to work out what has actually been measured for each. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision.

Is There a Head-to-Head Randomized Trial?

No. Within the verified literature available here, there is no randomized controlled trial that enrolled a single population, randomized participants to an Ipamorelin arm and a GHRP-2 arm, and reported a shared primary endpoint such as peak growth hormone concentration, IGF-1 change or body composition change. Because no such trial exists in this evidence set, no statement about one peptide outperforming the other on a clinical endpoint can be supported, and none is made here.

What does exist is a set of studies that examined several growth hormone releasing peptides in parallel in the laboratory. A urinary metabolite study administered GHRP-1, GHRP-2, GHRP-6, Hexarelin and Ipamorelin nasally to human volunteers and characterised the excreted metabolites of each compound (PMID 25869809). That design placed both peptides in the same protocol, but the endpoint was analytical detection of metabolites for doping control purposes, not a therapeutic or hormonal outcome, so it is not a head-to-head efficacy comparison.

Side-by-Side: What Each Evidence Base Contains

Shared Mechanism: Ghrelin Receptor Agonism

Both peptides belong to the growth hormone secretagogue family, which acts at the growth hormone secretagogue receptor rather than at the growth hormone releasing hormone receptor. A structure activity relationship analysis of peptidic growth hormone secretagogues examined how sequence modifications across this family relate to receptor activity and reported that small structural changes alter the behaviour of these compounds (PMID 26811125). That paper provides the clearest published framework for understanding why Ipamorelin and GHRP-2 are grouped together despite differing sequences.

A 2020 review of growth hormone secretagogues in the management of body composition in hypogonadal males described the class as acting on the growth hormone and IGF-1 axis and discussed the rationale that has driven interest in these compounds, while noting the limits of the supporting clinical data (PMID 32257855). A 2026 review of performance enhancing peptides modulating the GH-IGF1 axis made a similar observation, describing a gap between the clinical evidence base and widespread patient self administration of these peptides (PMID 42395176).

Where the Two Differ in the Literature

GHRP-2 appears more frequently in anti-doping analytical work, which reflects its longer presence on prohibited substance lists and in seized material. Researchers developed a high throughput LC-MS/MS screen for growth hormone releasing peptides in equine and human urine that used peptide derivatization to improve chromatography (PMID 24574167), and a separate method quantified seven bioactive peptides in horse plasma by liquid chromatography mass spectrometry (PMID 23318763). Ipamorelin appears in broader peptide screening approaches, including a method that simplified and expanded screening for peptides below 2 kDa through direct urine injection, liquid chromatography and ion mobility mass spectrometry (PMID 26578461).

Study Designs Reported in the Verified Literature

The table below summarises published study designs. These are descriptions of what researchers did in cited work, not protocols for any reader.

No verified paper in this set reports a milligram or microgram dose of Ipamorelin or GHRP-2 within its title or abstract scope, so no numeric dose is stated on this page for either peptide.

Regulatory Status

Neither Ipamorelin nor GHRP-2 is an approved prescription medicine for growth hormone deficiency or body composition indications. The 2026 review of GH-IGF1 axis peptides described these compounds as circulating largely through self administration channels rather than through approved clinical pathways and framed that as a safety concern for clinicians (PMID 42395176). A 2026 narrative review of peptides in urology and sexual medicine similarly examined clinical effectiveness, dosing practices, indications and safety across peptide categories and highlighted the limited regulatory footing of many marketed peptides (PMID 42862021).

Both peptides are also relevant to sport anti-doping programmes, which is why so much of the published work on each concerns detection methods rather than therapeutic outcomes (PMID 24574167).

Product Quality Findings

Two analytical studies examined material sold outside regulated supply chains. An analysis of new growth promoting black market products examined what such products actually contained (PMID 29864719), and a separate investigation identified glycine modified growth hormone secretagogues in seized doping material, indicating that structurally altered analogues circulate alongside the named parent peptides (PMID 30136411). These findings apply to the secretagogue category broadly rather than distinguishing between Ipamorelin and GHRP-2.

Adverse Events: What Studies Report

The verified evidence base contains review level safety discussion rather than controlled safety trials for either peptide individually.

• The 2020 review of growth hormone secretagogues in hypogonadal male body composition management discussed the class alongside androgen directed approaches and noted that the supporting safety and efficacy data for secretagogues remained limited relative to established therapies (PMID 32257855).
• The 2026 review of performance enhancing peptides modulating the GH-IGF1 axis reported a gap between available clinical evidence and the scale of patient self administration, and framed unmonitored use as the central safety issue for this class (PMID 42395176).
• The 2026 narrative review covering peptides in urology and sexual medicine assessed clinical effectiveness, dosing, indications and safety and reported that evidence quality varied substantially across the peptides reviewed (PMID 42862021).
• Analytical work on black market growth promoting products raised product identity and content concerns that are separate from the pharmacology of either peptide (PMID 29864719).

No verified study in this set reported a comparative adverse event rate between Ipamorelin and GHRP-2, so no such comparison is offered.

How to Read This Comparison

Comparison questions usually assume that a trial somewhere ranked two options. For Ipamorelin and GHRP-2 that trial has not been published in the verified literature here. What is available is a shared mechanistic classification (PMID 26811125), parallel analytical characterisation including one protocol that administered both to human volunteers for metabolite profiling (PMID 25869809), and review level commentary noting that clinical evidence lags behind real world use (PMID 42395176). Any individual question about these compounds belongs with a licensed physician who can evaluate the full clinical picture.

References

• Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males (Translational Andrology and Urology, 2020)
• Metabolism of growth hormone releasing peptides (Analytical Chemistry, 2012)
• The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration (Frontiers in Endocrinology, 2026)
• Analysis of new growth promoting black market products (Growth Hormone & IGF Research, 2018)
• Structure-activity relationship for peptidic growth hormone secretagogues (Drug Testing and Analysis, 2017)
• Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review (Sexual Medicine Reviews, 2026)
• Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin (Drug Testing and Analysis, 2015)
• Glycine-modified growth hormone secretagogues identified in seized doping material (Drug Testing and Analysis, 2019)
• Determination of growth hormone releasing peptides (GHRP) and their major metabolites in human urine for doping controls by means of liquid chromatography mass spectrometry (Analytical and Bioanalytical Chemistry, 2011)
• Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry (Journal of Separation Science, 2016)
• A high-throughput LC-MS/MS screen for GHRP in equine and human urine, featuring peptide derivatization for improved chromatography (Drug Testing and Analysis, 2014)
• Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry (Analytical and Bioanalytical Chemistry, 2013)